首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.
【2h】

Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.

机译:口服和静脉内给药后一种新的β-肾上腺素能受体拮抗剂倍他洛尔(SL 75212)的血药浓度和药效学作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1 In normal subjects, intravenous betaxolol given in doses which inhibited the tachycardia of exercise failed to affect the peak expiratory flow rate. 2 From 2 to 48 h after administration of 150 micrograms/kg in four normal subjects, there was no significant difference between the blood levels, whether given orally or intravenously. 3 At all times, heart rate and blood pressure, at rest and during exercise, were reduced equally after administration by both routes, but the area under the curve of exercise heart rate against time was significantly smaller (P < 0.05) after intravenous drug. 4 The absolute bioavailability of betaxolol was 89 +/- 5%.
机译:1在正常受试者中,以抑制运动性心动过速的剂量静脉注射紫杉醇无法影响呼气峰值流速。 2在四个正常受试者中,以150微克/千克的剂量给药后2至48小时,无论是口服还是静脉注射,血药浓度之间均无显着差异。 3两种途径给药后,在任何时候,静息和运动期间的心率和血压均会同时降低,但静脉注射药物后,运动心率与时间的关系曲线下的面积明显较小(P <0.05)。 4紫杉醇的绝对生物利用度为89 +/- 5%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号